* ReShape Lifesciences Inc RSLS.OQ RSLS.O is expected
to show
a fall in quarterly revenue when it reports results on November
14.
* The San Clemente California-based company is expected to
report
a 2.5% decrease in revenue to $3.617 million from $3.71 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for ReShape
Lifesciences Inc
is for a loss of 35 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for ReShape
Lifesciences Inc is $1.63, above its last closing price
of $0.22.
This summary was machine generated November 11 at 16:38 GMT.
All figures in US dollars unless otherwise stated